Toncoin has plunged below $2, rattling investors as regulatory warnings and technical weaknesses converge, raising fears of a prolonged correction in the volatile crypto market.Toncoin has plunged below $2, rattling investors as regulatory warnings and technical weaknesses converge, raising fears of a prolonged correction in the volatile crypto market.

Toncoin (TON) Price Prediction: Toncoin Slips Below $2 Amid Nasdaq Warning, But Oversold RSI Hints at Rebound

The Nasdaq issued a notice to TON Strategy Co. for bypassing shareholder approval on a $558 million private placement used to acquire Toncoin. The move triggered panic selling, pushing the token below a key support level and highlighting the risks associated with governance lapses in crypto-linked public firms. The PIPE deal, originally intended to establish the first listed TON treasury, had initially boosted optimism, but the warning has now intensified uncertainty.

Technical Breakdown: Oversold Conditions Signal Potential Rebound

Toncoin’s failure to maintain levels above $2 marks a significant technical concern. Recent trading shows the token hovering around $1.96, breaching support after briefly rebounding from October lows. The Relative Strength Index (RSI) has dipped into oversold territory below 30, signaling that a tactical short-term recovery could be on the horizon.

Nasdaq’s warning to TON Strategy Co. over an unapproved $558M PIPE purchase triggered panic selling, pushing Toncoin below $2 and highlighting fragile market sentiment. Source: @Davide_Martini0 via X

High trading activity and increased netflows during the decline reflect strong selling pressure, yet analysts note that if the $1.80 support holds, Toncoin could experience a bounce. A recovery above $2 may provide temporary relief for traders and help stabilize market sentiment, although the broader trend remains cautious. The oversold RSI thus offers a window of opportunity amid prevailing market fear.

Broader Market Context

Toncoin’s recent decline coincides with heightened volatility across the broader cryptocurrency market. October 2025 witnessed dramatic swings, including Bitcoin’s peak near $126,000, followed by substantial sell-offs, wiping out billions in value and reinforcing a risk-averse trading environment. These factors contributed to Toncoin’s 13.8% weekly decline and ongoing hesitation among buyers.

Toncoin has fallen below $2 for the first time since its October crash. Source: @DurovPD via X

Investor sentiment remains fragile, particularly for tokens tied to institutional or corporate developments. Toncoin’s drop illustrates the market’s sensitivity to regulatory warnings, large-scale transactions, and overall sector volatility. Traders are closely monitoring the Ton blockchain ecosystem to determine whether the token can regain stability or face further downward pressure.

Outlook: Cautious Optimism Despite Fear

The Toncoin price prediction remains cautious in the near term. Regulatory concerns and the breakdown of key support levels have created a bearish backdrop, yet technical indicators such as oversold RSI readings suggest the potential for a short-term bounce. Holding $1.80 could pave the way for a recovery toward $2.30, offering tactical opportunities for traders.

Toncoin was trading at around $1.94, down 3.96% in the last 24 hours. Source: Brave New Coin

Toncoin now sits at a pivotal point where market fear meets potential opportunity. Investors should track regulatory updates and trading sentiment closely, as these will dictate whether the token stabilizes or continues to decline. While the $2 breakdown signals caution, oversold conditions hint at a possible rebound, making the coming days critical for Toncoin’s short-term trajectory

Market Opportunity
TONCOIN Logo
TONCOIN Price(TON)
$1.713
$1.713$1.713
-2.00%
USD
TONCOIN (TON) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26